Market Update (NYSE:LLY): Lilly Announces Webcast to Discuss Abemaciclib Data

[PR Newswire] – INDIANAPOLIS, May 31, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) will conduct a webcast on June 9 to discuss the abemaciclib data presented at the American Society of Clinical Oncology (ASCO) … Read more on this. Eli Lilly and Company (LLY) , currently valued at $79.18B, opened this morning at $75.01. During the trading session, LLY traded between $74.71 to $75.63 with its 52-week range being $67.88 to $92.85. Lilly (LLY) shares are currently priced at 21.06x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -0.14x earnings multiple for the same period. And for passive income investors, the company pays shareholders $2.04 per share annually in dividends, yielding 2.72%. In a review of the consensus earnings estimate this quarter, 17 sell-side analysts are looking at $0.85 per share, which would be $0.05 worse than the year-ago quarter and a $0.02 sequential decrease. Investors should also note that the full-year EPS estimate of $3.56 is a $0.13 better when compared to the previous year’s annual results. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $5.14 Billion. If realized, that would be a 3.21% increase over the year-ago quarter. Recently, Societe Generale Initiated LLY at Hold (Apr 6, 2016). Previously, BMO Capital Markets upgraded LLY from Market Perform to Outperform. Investors should keep in mind is that the average price target is $95.71, which is 27.60% above where the stock opened this morning. See more in (NYSE:LLY) Similar Articles: Market Update: Eli Lilly & Company (NYSE:LLY) – Lilly’s Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Moderate-to-Severe Plaque Psoriasis Market Update (NYSE:LLY): Lilly to Present Phase 3 Data at the American Academy of Dermatology (AAD) Annual Meeting for Ixekizumab in Psoriasis and Psoriatic Arthritis Market Update: Eli Lilly & Company (NYSE:LLY) – U.S. FDA Accepts Filing of Cardiovascular Outcomes Data for Jardiance® (empagliflozin)